slides · global inventory
Chart
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 78,138
Current window 61,621-61,650
Pages 2,605
Rows per page 30
Component
61,621-61,650 of 78,138
30
PoS stands for Probability of Success. The slide uses a comparative timeline framework to illustrate efficiency gains.Absci | Investor Presentation Deck | 37 slides · Absci
Pitch deck Investor relations 1 hit
31
The chart uses a dot-plot style to represent cash flow magnitude over time, color-coded by development stage.Absci | Investor Presentation Deck | 37 slides · Absci
Pitch deck Investor relations 1 hit
06
The slide uses a donut chart to visualize the revenue split between the two segments.Advantage Solutions | Investor Presentation Deck | 27 slides · Advantage Solutions
Pitch deck Investor relations 1 hit
07
The slide uses a donut chart to illustrate market concentration and lists key service offerings for four business units.Advantage Solutions | Investor Presentation Deck | 27 slides · Advantage Solutions
Pitch deck Investor relations Beat · Market Size1 hit
08
The slide uses a donut chart to illustrate market dominance.Advantage Solutions | Investor Presentation Deck | 27 slides · Advantage Solutions
Pitch deck Investor relations Beat · Market Size1 hit
10
The slide uses a grid-like layout to compare three business segments over four quarters in 2022, showing both absolute dollar values and percentage growth.Advantage Solutions | Investor Presentation Deck | 27 slides · Advantage Solutions
Pitch deck Investor relations 1 hit
11
The slide uses a donut chart to show revenue distribution and maps these segments to specific pricing strategies.Advantage Solutions | Investor Presentation Deck | 27 slides · Advantage Solutions
Pitch deck Investor relations Beat · Business Model1 hit
13
Includes CAGR metrics for specific periods and highlights key acquisition and economic events.Advantage Solutions | Investor Presentation Deck | 27 slides · Advantage Solutions
Pitch deck Investor relations 1 hit
14
Includes Y/Y growth percentages and margin percentages for each segment.Advantage Solutions | Investor Presentation Deck | 27 slides · Advantage Solutions
Pitch deck Investor relations 1 hit
17
The chart highlights two key conversion rates: Unlevered FCF (~59%) and Levered FCF (Pre-M&A) (~19%).Advantage Solutions | Investor Presentation Deck | 27 slides · Advantage Solutions
Pitch deck Investor relations 1 hit
19
Includes a stacked bar chart showing debt maturity and a table detailing debt instruments and equity components.Advantage Solutions | Investor Presentation Deck | 27 slides · Advantage Solutions
Pitch deck Investor relations 1 hit
05
Advantage Solutions | Results Presentation Deck | 13 slidesAdvantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · OverviewLoop · So What Cascade1 hit
07
Includes a waterfall-style chart showing debt components and a detailed table for debt and equity.Advantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Capitalization Summary1 hit
05
The slide uses a Gantt-style chart to represent clinical trial progress for three distinct programs.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Golden Circle1 hit
12
The chart shows a clear dose-response relationship between 1.0 mg/kg and 10.0 mg/kg doses, with statistical significance marked at early time points.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
21
The slide uses a heatmap to visualize individual patient outcomes, a common technique in clinical trial reporting.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
29
The slide uses a Kaplan-Meier survival curve and a comparative table to illustrate the severity of the disease.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
30
Includes histological images of liver tissue and a dot plot showing BMD improvement.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
33
The slide uses a box plot to visualize longitudinal clinical trial data.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
39
The slide uses a split-screen layout: left side is market sizing/segmentation, right side is a 2x2 strategic framework for launch execution.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
08
Uses a 2x2-style quadrant map to illustrate competitive advantage.Aeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations Loop · Aha Moment1 hit
08
The chart shows a steady upward trend in weekly total prescriptions (TRx) over 73 weeks.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & Proof1 hit
10
The slide combines a treatment indication matrix with a donut chart illustrating patient symptom prevalence.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & Proof1 hit
12
Alkermes | Investor Presentation Deck | 32 slidesAlkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & Proof1 hit
13
Includes product branding, dosage options, and a bar chart showing revenue growth.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & Proof1 hit
14
Includes a callout regarding COVID-19 impact on 2020 sales.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & Proof1 hit
15
Alkermes | Investor Presentation Deck | 32 slidesAlkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & Proof1 hit
20
The heatmaps visualize EEG frequency power over time, with red indicating high power (arousal) and blue indicating low power.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
29
The chart illustrates the shift from a single-product revenue base to a more diversified portfolio including VIVITROL, ARISTADA, VUMERITY, and LYBALVI.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
30
Includes disclaimer regarding non-GAAP reconciliation and specific business context (oncology spin-off, INVEGA royalties).Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit